Tags

Type your tag names separated by a space and hit enter

Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
Vaccine. 2010 Oct 08; 28(43):7063-9.V

Abstract

To determine the clinical efficacy and cost-saving effect of pneumococcal polysaccharide vaccine (PPV) against community-acquired pneumonia (CAP), an open-label, randomized clinical trial was conducted involving 786 Japanese subjects older than 65 years of age receiving a routine influenza vaccine during the 2-year period. Study subjects were randomly assigned to either a PPV group (n=394) or to a non-PPV group (n=392). The incidence, admission and the medical cost for all-cause pneumonia were compared between these two groups. PPV vaccination significantly reduced the incidence of admission for all-cause pneumonia for subjects older than 75 years of age (41.5%, P=0.039) and for those who had difficulty walking (62.7%, P=0.005), but not for all study subjects older than 65 years of age (P=0.183), for the 2-year period. The Kaplan-Meier survival curves for subjects who had difficulty walking free from all-cause pneumonia demonstrated a significant difference (P=0.0146) between the two groups. PPV vaccination significantly reduced medical costs for all study subjects during the first year period (P=0.027). Our present data demonstrated that PPV was effective for all-cause pneumonia for study subjects older than 75 years of age, although the effect was not significant for all study subjects older than 65 years of age.

Authors+Show Affiliations

Department of Respiratory Medicine, Nagasaki Kawatana Medical Center, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20723631

Citation

Kawakami, Kenji, et al. "Effectiveness of Pneumococcal Polysaccharide Vaccine Against Pneumonia and Cost Analysis for the Elderly Who Receive Seasonal Influenza Vaccine in Japan." Vaccine, vol. 28, no. 43, 2010, pp. 7063-9.
Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28(43):7063-9.
Kawakami, K., Ohkusa, Y., Kuroki, R., Tanaka, T., Koyama, K., Harada, Y., Iwanaga, K., Yamaryo, T., & Oishi, K. (2010). Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine, 28(43), 7063-9. https://doi.org/10.1016/j.vaccine.2010.08.010
Kawakami K, et al. Effectiveness of Pneumococcal Polysaccharide Vaccine Against Pneumonia and Cost Analysis for the Elderly Who Receive Seasonal Influenza Vaccine in Japan. Vaccine. 2010 Oct 8;28(43):7063-9. PubMed PMID: 20723631.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. AU - Kawakami,Kenji, AU - Ohkusa,Yasushi, AU - Kuroki,Reiki, AU - Tanaka,Takeshi, AU - Koyama,Kazuhiko, AU - Harada,Yoshitaka, AU - Iwanaga,Kouichi, AU - Yamaryo,Takeshi, AU - Oishi,Kazunori, Y1 - 2010/08/17/ PY - 2010/04/22/received PY - 2010/07/29/revised PY - 2010/08/02/accepted PY - 2010/8/21/entrez PY - 2010/8/21/pubmed PY - 2010/12/31/medline SP - 7063 EP - 9 JF - Vaccine JO - Vaccine VL - 28 IS - 43 N2 - To determine the clinical efficacy and cost-saving effect of pneumococcal polysaccharide vaccine (PPV) against community-acquired pneumonia (CAP), an open-label, randomized clinical trial was conducted involving 786 Japanese subjects older than 65 years of age receiving a routine influenza vaccine during the 2-year period. Study subjects were randomly assigned to either a PPV group (n=394) or to a non-PPV group (n=392). The incidence, admission and the medical cost for all-cause pneumonia were compared between these two groups. PPV vaccination significantly reduced the incidence of admission for all-cause pneumonia for subjects older than 75 years of age (41.5%, P=0.039) and for those who had difficulty walking (62.7%, P=0.005), but not for all study subjects older than 65 years of age (P=0.183), for the 2-year period. The Kaplan-Meier survival curves for subjects who had difficulty walking free from all-cause pneumonia demonstrated a significant difference (P=0.0146) between the two groups. PPV vaccination significantly reduced medical costs for all study subjects during the first year period (P=0.027). Our present data demonstrated that PPV was effective for all-cause pneumonia for study subjects older than 75 years of age, although the effect was not significant for all study subjects older than 65 years of age. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/20723631/Effectiveness_of_pneumococcal_polysaccharide_vaccine_against_pneumonia_and_cost_analysis_for_the_elderly_who_receive_seasonal_influenza_vaccine_in_Japan_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)01119-9 DB - PRIME DP - Unbound Medicine ER -